vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer
December 13 2022 - 8:15AM
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage
biopharmaceutical company focused on the development of orally
administered treatments for type 1 diabetes (T1D), today announced
the appointment of Steven Tuch as Chief Financial Officer,
effective immediately.
“Steven’s success in capital raising and business development,
combined with his range of work in the life science and healthcare
industry, makes us confident that he is an excellent fit for the
position and our needs,” said Paul Sekhri, President and Chief
Executive Officer of vTv Therapeutics. “We anticipate that he will
play a pivotal role as we actively prepare to initiate, then
execute on, our Phase 3 trials for our lead drug candidate, TTP399.
On behalf of our board and executive team, I welcome Steven to
vTv.”
Mr. Tuch has had a distinguished career with more than 20 years
of financial and business development experience with multiple life
science companies through various stages of financial planning and
development. Prior to joining vTv, he served as Head of Corporate
Development at Rallybio Corporation, leading the Company through
its $92.7 million IPO in July 2021. Before joining Rallybio, he
held several leadership roles at BMO Capital Markets including over
seven years as Managing Director, Head of Healthcare Equity Capital
Markets, and completed more than 140 transactions, raising over $20
billion. Prior to BMO, Mr. Tuch held the position of Managing
Director, Head of Healthcare Equity Capital Markets of Deutsche
Bank Securities as well as Head of Consumer and Business Services
Equity Capital Markets and Head of Private Placements, where he
established the firm's private equity placement. Prior to that
role, he served as Head of Private Placement Group of Thomas Weisel
Partners (now Stifel) for six years managing the firm’s structured
equity products activity, including private equity placements,
unregistered common stock PIPEs, registered directs and private
converts. Mr. Tuch earned an MBA from Stanford University’s
Graduate School of Business and a BBA from the University of
Michigan.
“I am thrilled to be joining vTv at this key juncture. With the
breakthrough therapy designation for TTP399, vTv’s lead clinical
program, the company has the potential to improve the quality of
life for T1D patients,” said Mr. Tuch. “I look forward to
contributing to the effort to advance TTP399 through its pivotal
trials and, in turn, to patients who could benefit from this
therapeutic program.”
About vTv TherapeuticsvTv Therapeutics Inc. is
a clinical stage biopharmaceutical company focused on developing
oral, small molecule drug candidates. vTv has a pipeline of
clinical drug candidates led by programs for the treatment of type
1 diabetes and cystic fibrosis related diabetes. vTv’s development
partners are pursuing additional indications in type 2 diabetes,
chronic obstructive pulmonary disease, renal disease, primary
mitochondrial myopathy, and pancreatic cancer. For more
information, please visit www.vtvtherapeutics.com.
Forward-Looking Statements
This release contains forward-looking statements, which involve
risks and uncertainties, including statements regarding the
potential grant of the FDA Approval. These forward-looking
statements can be identified by the use of forward-looking
terminology, including the terms “anticipate,” “believe,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “will,” “would” and, in
each case, their negative or other various or comparable
terminology. All statements other than statements of historical
facts contained in this release, including statements regarding the
agreements and transactions described in this release are
forward-looking statements. These statements involve known and
unknown risks, uncertainties and other important factors, including
the risk that the FDA Approval is not received on a timely basis or
at all, that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Important factors that could cause our
results to vary from expectations include those described under the
heading “Risk Factors” in our Annual Report on Form 10-K and our
other filings with the SEC. These forward-looking statements
reflect our views with respect to future events as of the date of
this release and are based on assumptions and subject to risks and
uncertainties. Given these uncertainties, you should not place
undue reliance on these forward-looking statements. These
forward-looking statements represent our estimates and assumptions
only as of the date of this release and, except as required by law,
we undertake no obligation to update or review publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise after the date of this release. We
anticipate that subsequent events and developments will cause our
views to change. Our forward-looking statements do not reflect the
potential impact of any future acquisitions, merger, dispositions,
joint ventures or investments we may undertake. We qualify all of
our forward-looking statements by these cautionary statements.
Contacts:
Investors:
Lee Roth
Burns McClellan
lroth@burnsmc.com
Media:
Selina Husain / Robert Flamm, Ph.D.
Burns McClellan, Inc.
shusain@burnsmc.com / rflamm@burnsmc.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/673af954-9fa5-49d1-a87f-b6ab56e0b7c1
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Mar 2024 to Apr 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Apr 2023 to Apr 2024